Vis enkel innførsel

dc.contributor.authorSchuster, Corneliaen_US
dc.contributor.authorEikesdal, Hans Petteren_US
dc.contributor.authorPuntervoll, Hanneen_US
dc.contributor.authorGeisler, Jürgenen_US
dc.contributor.authorGeisler, Stephanieen_US
dc.contributor.authorMolven, Andersen_US
dc.contributor.authorAkslen, Lars A.en_US
dc.PublishedPLoS ONE 7(6): e38364eng
dc.description.abstractBackground: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma. Methods and Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease >6 months (14%) while 24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%). Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12–49). Seven of the 11 patients experiencing DC developed early hypertension (<2 months) compared to 3/24 of patients with PD (P = 0.001), and hypertension was associated with PFS (P = 0.005) and OS (P = 0.013). Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab.en_US
dc.publisherPublic Library of Scienceeng
dc.relation.ispartof<a href="" target="blank">Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab</a>
dc.rightsAttribution CC BYeng
dc.titleClinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertensionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2012 Schuster et al.

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY